Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

January 15, 2010

mondoBIOTECH holding AG: the extraordinary shareholders' meeting approves all of the Board of Directors’ proposals

Stans, Switzerland - January 15, 2010. The shareholders of mondoBIOTECH holding AG have unanimously approved two amendments to the Company's articles of incorporation at today's extraordinary shareholders' meeting, one relating to the usage of conditional share capital, and the other required due to the entry into force of the new Intermediated Security Act. Usage of conditional share capital The shareholders' meeting has approved the amendment to the articles of incorporation regarding the usage of the Company's existing conditional share capital. The amended art. 3b para. 2 of the articles of incorporation now creates the possibility to grant option rights to existing and/or new shareholders in connection with future capital increases which shall be covered by the Company's already existing conditional share capital. This amendment provides the Board of Directors with more flexibility in the procurement of capital. The first issuance of option rights pursuant to the amendment approved today is expected to be conducted in conjunction with the rights offering planned for the end of January 2010 (see also press release of yesterday, 14 January 2010). Form of the shares The shareholders' meeting approved a second amendment to the articles of incorporation. Art. 4 of the articles of incorporation relating to the form of the shares has been amended to comply with the new Swiss Intermediated Security Act which entered into force on 1 January 2010. "We thank all our shareholders for their confidence in the Board of Directors and in the Company" said Fabio Cavalli, CEO and member of the Board of Directors of mondoBIOTECH holding AG. About Mondobiotech Mondobiotech (mondoBIOTECH holding AG: SIX: RARE/ISIN:CH0101910732), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: Dr. Yvonne Gunsch-Wegmann, MBA Head of External Relations mondoBIOTECH holding AG Das Kloster Mürgstrasse 18 CH-6370 - Stans - Switzerland T   +41 (0)840 200 010 F   +41 (0)41 611 09 34 M  +41 (0)79 414 39 33 investor@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your Download the Newsletter in the pdf format

Back to list